| Similar Articles |
|---|
 |
The Motley Fool
June 3, 2004
Brian Gorman |
Spitzer Chases Glaxo Did the drug company GlaxoSmithKline withhold information about the effects of Paxil in children? No doubt the bad publicity will continue to hit the stock.   |
The Motley Fool
September 16, 2004
Alyce Lomax |
Depressing Days for Drug Makers? Is black-box labeling of antidepressants going to curtail the mammoth industry? |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
The Motley Fool
May 18, 2009
Brian Orelli |
Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship. |
Pharmaceutical Executive
March 1, 2009
Jill Wechsler |
Through the Looking Glass Pharma relations with researchers are critical for developing new technology, and reformers will discourage inappropriate relationships by making any links to pharmaceutical marketing known to all. |
The Motley Fool
March 23, 2004
W.D. Crotty |
Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
The Motley Fool
September 8, 2008
Rich Duprey |
The Coming Great Pharma Panic The FDA's drug warning list provides dangerously little information. |
The Motley Fool
November 13, 2009
Brian Orelli |
Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant. |
The Motley Fool
November 19, 2008
Brian Orelli |
Depressing News for Drugmakers Antidepressants aren't that different from each other, says a recent report. |
ifeminists
October 5, 2008
Tony Zizza |
The over-prescribing of America In writing "Stigma often hinders lifesaving discussion" for The Tennessean on Sept. 17, Dr. Dennis Morrison offers us more recycled bromides concerning suicide and the state of mental health. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
American Family Physician
August 1, 2006 |
Antidepressant Discontinuation Syndrome: What You Should Know A patient guide: What is antidepressant discontinuation syndrome?... Which antidepressants can cause this problem?... What can I do if I have antidepressant discontinuation syndrome?... etc. |
The Motley Fool
September 30, 2010
Brian Orelli |
Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason. |
